SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.Pamrevlumab (FibroGen) is a fully human monoclonal antibody that impedes connective tissue growth factor, according to researchers.
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant.
Stem Cell Transplant Boosts Outcome in Juvenile Sclerosis miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Study shows stem cell transplant significantly improves outcomes in refractory juvenile systemic sclerosis medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Prevalence of DED in patients with both limited and diffuse subtypes of systemic sclerosis & determining the predictive factors associated with the occurrence.